Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer (vol 12, 125, 2019)

被引：0
|
作者：
Wu, Huan [1 ,2 ]
Li, Rongrong [1 ,2 ]
Zhang, Zhiwei [1 ,2 ]
Jiang, Huiyang [1 ,2 ]
Ma, Hanlin [1 ,2 ]
Yuan, Cunzhong [1 ,2 ]
Sun, Chenggong [1 ,2 ]
Li, Yingwei [1 ,2 ]
Kong, Beihua [1 ,2 ]
机构：
[1] Shandong Univ, Qilu Hosp, Dept Obstet & Gynecol, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China
[2] Shandong Univ, Qilu Hosp, Shandong Key Lab Gynecol Oncol, Jinan, Shandong, Peoples R China
来源：
JOURNAL OF OVARIAN RESEARCH | 2020年 / 13卷 / 01期
关键词：
D O I：
10.1186/s13048-020-00628-5
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
The original article [1] contains errors in Fig. 3C, Results and Discussion.
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months
    Rizzo, Stefania
    Botta, Francesca
    Raimondi, Sara
    Origgi, Daniela
    Buscarino, Valentina
    Colarieti, Anna
    Tomao, Federica
    Aletti, Giovanni
    Zanagnolo, Vanna
    Del Grande, Maria
    Colombo, Nicoletta
    Bellomi, Massimo
    EUROPEAN RADIOLOGY, 2018, 28 (11) : 4849 - 4859
  • [22] Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months
    Stefania Rizzo
    Francesca Botta
    Sara Raimondi
    Daniela Origgi
    Valentina Buscarino
    Anna Colarieti
    Federica Tomao
    Giovanni Aletti
    Vanna Zanagnolo
    Maria Del Grande
    Nicoletta Colombo
    Massimo Bellomi
    European Radiology, 2018, 28 : 4849 - 4859
  • [23] WTAP is a prognostic marker of high-grade serous ovarian cancer and regulates the progression of ovarian cancer cells
    Yu, Hai-Lan
    Ma, Xu-Dong
    Tong, Jin-Fei
    Li, Jian-Qiong
    Guan, Xiao-Jing
    Yang, Jian-Hua
    ONCOTARGETS AND THERAPY, 2019, 12 : 6191 - 6201
  • [24] Epigenomic signatures of acquired platinum resistance in high grade serous ovarian cancer
    Fang, Fang
    Cardenas, Horacio
    Jiang, Guanglong
    Perkins, Susan M.
    Zhang, Chi
    Keer, Harold
    Liu, Yunlong
    Matei, Daniela
    Nephew, Kenneth
    CANCER RESEARCH, 2018, 78 (13)
  • [25] The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer
    Ng, Charlotte K. Y.
    Cooke, Susanna L.
    Howe, Kevin
    Newman, Scott
    Xian, Jian
    Temple, Jillian
    Batty, Elizabeth M.
    Pole, Jessica C. M.
    Langdon, Simon P.
    Edwards, Paul A. W.
    Brenton, James D.
    JOURNAL OF PATHOLOGY, 2012, 226 (05): : 703 - 712
  • [26] Differentially expressed genes in platinum-resistant high-grade serous ovarian cancer
    Corey, Logan
    Alvero, Ayesha
    Tiwari, Nivedita
    You, Yuan
    Rattan, Ramandeep
    Kim, Seongho
    Mor, Gil
    Gogoi, Radhika
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S130 - S131
  • [27] High-grade serous Ovarian Cancer: TP53 Mutations and Platinum Response
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (07)
  • [28] Characterisation of Proteomic heterogeneity following platinum therapy in High-grade Serous Ovarian Cancer
    Wulandari, Ratri
    Nixon, Katherine
    Rama, Nona
    Curry, Ed
    Cunnea, Paula
    Fotopoulou, Christina
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2022, 129 : 40 - 41
  • [29] Histopathology and proteomics are synergistic for high-grade serous ovarian cancer platinum response prediction
    Kilim, Oz
    Olar, Alex
    Biricz, Andras
    Madaras, Lilla
    Pollner, Peter
    Szallasi, Zoltan
    Sztupinszki, Zsofia
    Csabai, Istvan
    NPJ PRECISION ONCOLOGY, 2025, 9 (01)
  • [30] Acquired chemotherapy resistance in high-grade serous ovarian cancer patients.
    Christie, Elizabeth L.
    Beach, Jessica
    Etemadmoghadam, Dariush
    Garsed, Dale
    Patch, Ann-Marie
    Fereday, Sian
    Pattnaik, Swetansu
    Brady, Samuel
    Bild, Andrea
    Bowtell, David D. L.
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 20 - 20
12345